Global X Robo Global Robotics & Automation ETF vs Smith & Nephew plc — how do they compare? Global X Robo Global Robotics & Automation ETF trades at $80.96 (market cap $2.06B), while Smith & Nephew plc trades at $27.09 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 5.4× Global X Robo Global Robotics & Automation ETF's market cap, and Smith & Nephew plc pays a 2.95% dividend while Global X Robo Global Robotics & Automation ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X Robo Global Robotics & Automation ETF for 36 Days and Smith & Nephew plc for 120 Days on average.
| ROBO | SNN | |
|---|---|---|
Market Cap | $2.06B | $11.10B |
Volume | 148,111 | 1,051,703 |
Sector | Sector/Thematic | Health |
52-Week High | $90.34 | $37.17 |
52-Week Low | $63.04 | $26.42 |
Typical Hold Time | 36 Days | 120 Days |
Enterprise Value | — | $14.13B |
Dividend Yield | — | 2.95% |
Signals from Pluang's Aura AI — not financial advice
ROBO trades at $81.82, down 1.89% today amid mixed technical signals. The overall technical outlook remains bullish with strong moving average support, though oscillators show bearish momentum with RSI levels above 79 indicating potential overbought conditions. Recent news highlights accelerating robotics adoption across manufacturing, healthcare, and military applications, with Q2 2026 earnings showing broadening demand for physical AI technologies.
The robotics ETF offers diversified exposure to a sector benefiting from labor shortages and AI infrastructure growth. Key risks include valuation concerns amid rapid sector expansion and potential market volatility. Analyst coverage remains positive on long-term robotics adoption trends, though current technical indicators suggest near-term consolidation may be needed after recent gains.
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →